Skip to Content

Juluca (dolutegravir / rilpivirine) Disease Interactions

There are 6 disease interactions with Juluca (dolutegravir / rilpivirine):

Moderate

Dolutegravir (applies to Juluca) hemodialysis

Moderate Potential Hazard, Moderate plausibility.

Dolutegravir has not been studied in patients on dialysis, so caution is recommended if used in these patients.

Moderate

Dolutegravir (applies to Juluca) hepatitis

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Infectious Hepatitis

Patients with underlying hepatitis B or C may be at increased risk for worsening or development of transaminase elevations with the use of dolutegravir. In some cases there was hepatitis B reactivation particularly in a setting where anti- hepatitis treatment was withdrawn. Appropriate laboratory testing prior to initiating treatment and monitoring for hepatotoxicity during therapy is recommended in patients with underlying hepatitis B or C.

Moderate

Dolutegravir (applies to Juluca) liver impairment

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

The effect of severe hepatic impairment (Child - Pugh C) on the pharmacokinetics of dolutegravir has not been studied, therefore dolutegravir is not recommended for use on these patients. No dosage adjustment is needed for patients with mild or moderate hepatic impairment.

Moderate

Rilpivirine (applies to Juluca) depression

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Psychosis

Depressive symptoms including suicide ideation and suicide attempts have been reported with the use of rilpivirine. Patients should be monitored for the appearance of these symptoms and should seek medical evaluation immediately if severe depressive symptoms occur. Caution should be used in patients with a history of depression or other psychiatric conditions.

Moderate

Rilpivirine (applies to Juluca) liver impairment

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

Hepatic adverse events have been reported in patients taking rilpivirine. Patients with underlying hepatitis B or C virus infection or marked transaminase elevations prior to therapy may be at increased risk for worsening or development of transaminase elevations; a few cases of hepatic toxicity have been reported in patients without preexisting hepatic disease or other known risk factors. Appropriate laboratory testing before starting therapy and monitoring for hepatotoxicity during therapy are recommended in patients with underlying hepatic disease (e.g., hepatitis B or C virus infection) or in patients with marked baseline transaminase elevations. Rilpivirine has not been studied in patients with severe liver dysfunction (Child-Pugh C); caution is recommended.

Moderate

Rilpivirine (applies to Juluca) renal impairment

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction

Rilpivirine should be used with caution and with increased monitoring for side effects in patients with severe renal dysfunction or end-stage renal disease, as drug concentrations can be increased due to alteration of drug absorption, distribution, and metabolism secondary to renal dysfunction. No dose adjustment is required in patients with mild or moderate renal dysfunction.

Juluca (dolutegravir / rilpivirine) drug interactions

There are 412 drug interactions with Juluca (dolutegravir / rilpivirine)

Juluca (dolutegravir / rilpivirine) alcohol/food interactions

There are 3 alcohol/food interactions with Juluca (dolutegravir / rilpivirine)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.